XELLIA PHARMACEUTICALS ApS: Financial statements 2022
CVR: 61094628
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
XELLIA PHARMACEUTICALS ApS (CVR 61094628) has filed annual accounts for 2022. In 2022, the company reported revenue of DKK 2,245,303,000 and a net result of DKK -371,486,000 compared with DKK -503,090,000 the year before. That is an increase of 25.3% compared with the year before. The profit margin was -16.5%. Equity in the 2022 report amounted to DKK 1,750,675,000. The solvency ratio was 50.6%. The company had 648 employees in the financial year.
- Revenue
- DKK 2,245,303,000
- Gross Profit
- DKK 318,378,000
- Profit/Loss
- DKK -371,486,000
- Equity
- DKK 1,750,675,000
- Total Assets
- DKK 3,460,247,000
- Employees
- 648
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | 2.2B | 318.4M | -371.5M | 1.8B | 648 |
| 2021 | 1.8B | -47M | -503.1M | 2.1B | 640 |
| 2020 | 2B | 361.3M | -115.7M | 2.6B | 624 |
| 2019 | 2.3B | 873.5M | 390.7M | 1.4B | 623 |
| 2018 | 1.9B | 576.7M | -74.9M | 1B | 580 |
Official annual report
Keep an eye on XELLIA PHARMACEUTICALS ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
XELLIA PHARMACEUTICALS ApS has published its annual report for 2021. Revenue came to DKK 1,792,626,000, and the net result was DKK -503,090,000.
As of March 25, 2022, Lone Thiis has joined the board of directors of XELLIA PHARMACEUTICALS ApS.
As of March 25, 2022, Martin Bech has joined the board of directors of XELLIA PHARMACEUTICALS ApS.
As of March 25, 2022, Gisli Lukas Ihlemann Lundahl has joined the board of directors of XELLIA PHARMACEUTICALS ApS.
As of March 25, 2022, Thomas Schou Hunderup has left the board of directors of XELLIA PHARMACEUTICALS ApS.
As of March 24, 2022, Lone Thiis has left the board of directors of XELLIA PHARMACEUTICALS ApS.
About XELLIA PHARMACEUTICALS ApS
XELLIA PHARMACEUTICALS ApS is a Danish company of the type Anpartsselskab based in København S, founded in 1959. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The company was previously named AXELLIA PHARMACEUTICALS ApS and ALPHARMA ApS. The management consists of Michael Kocher. The board consists of Søren Hostrup (chair), Alexander Sebastian Benjamin Sproedt, Hugo Mendes Marques Crespo Dos Reis and Lars Beck Madsen. The company is owned by XELLIA GROUP ApS. The company has 461 employees (2026). In 2025, the company reported revenue of DKK 1,461,516,000 and a net result of DKK 213,738,000 compared with DKK 828,966,000 the year before. Equity in the 2025 report amounted to DKK 404,569,000.
